Brief: Talaris Therapeutics Presents Additional Phase 2 Data And Analyses At American Transplant Congress 2022
07/06/2022 21:39
Talaris Therapeutics Inc TALS.O :
* TALARIS THERAPEUTICS PRESENTS ADDITIONAL PHASE 2 DATA AND
ANALYSES AT AMERICAN TRANSPLANT CONGRESS 2022
* TALARIS THERAPEUTICS INC - UPDATE ON FREEDOM-1 STUDY
ORIGINALLY
PLANNED FOR JUNE 8 NOW RESCHEDULED TO JUNE 30
Source text for Eikon: ID:nGNX6XDjz4
Further company coverage: TALS.O
Recent news on Tourmaline Bio
See all newsBrief: Novartis Completes Acquisition Of Tourmaline Bio
Brief: Novartis Announces Expiration Of Tourmaline Bio Tender Offer
Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports (updated)
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Tourmaline Bio
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy